medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 5

<< Back Next >>

Ann Hepatol 2015; 14 (5)

Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MDR3

Frider B, Castillo A, Gordo-Gilart R, Bruno A, Amante M, Alvarez L, Mathet V

Language: English
References: 18
Page: 745-751
PDF size: 222.66 Kb.


ABSTRACT

Introduction. Progressive familial intrahepatic cholestasis type 3 (PFIC-3) is a severe liver disorder associated with inherited dysfunction of multidrug resistance protein 3 (MDR3/ABCB4), which functions as a phospholipid floppase, translocating phosphatidylcholine from the inner to the outer hemileaflet of the canalicular membrane of hepatocytes. MDR3 deficiency results in a disbalanced bile which may damage the luminal membrane of cells of the hepatobiliary system. We evaluated clinical, biochemical and histological improvement in a genetically proven PFIC-3 patient after long-term ursodeoxycholic acid (UDCA) administration. Material and methods. A PFIC-3 patient and a relative with cholestatic liver disease were studied. Hepatic MDR3 expression was analyzed by immunohistochemistry and ABCB4 mutations were identified. The effect of the mutations on MDR3 expression and subcellular localization was studied in vitro. Results. A 23-year-old man presented cholestasis with severe fibrosis and incomplete cirrhosis. Canalicular staining for MDR3 was faint. Sequence analysis of ABCB4 revealed two missense mutations that reduce drastically protein expression levels. After 9 years of treatment with UDCA disappearance of fibrosis and cirrhosis was achieved. Conclusion. These data indicate that fibrosis associated with MDR3 deficiency can be reversed by long-term treatment with UDCA, at least when there is residual expression of the protein.


REFERENCES

  1. Jacquemin E. Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol 2012; 36: 26-35.

  2. Daleke D. Regulation of transbilayer plasma membrane phospholipid asymmetry. J Lipid Res 2003; 44: 233-42.

  3. Chan J, and VandeBerg J. Hepatobiliary transport in health and disease. Clin Lipidol 2012; 7: 189-202.

  4. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis 2010; 30:134-46.

  5. Sundaram SS, Sokol RJ. The Multiple Facets of ABCB4 (MDR3) Deficiency. Curr Treat Options Gastroenterol 2007; 10: 495-503.

  6. Stapelbroek J, van Erpecum K, Klomp L, Houwen R. Liver disease associated with canalicular transport defects: Current and future therapies. J Hepatol 2010; 52: 258-71.

  7. Jacquemin E, De Vree JM, Cresteil D, Sokal E, Sturm E, Dumont M, Scheffer G, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001; 120: 1448-58.

  8. Colombo C, Vajro P, Degiorgio D, Coviello D, Costantino L, Tornillo L, Motta V, et al. Clinical features and genotype- phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations. J Pediatr Gastroenterol Nutr 2011; 52: 73-83.

  9. Oude Elferink RP, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch 2006; 453: 601-10.

  10. Gonzales E, Davit-Spraul A, Baussan C, Buffet C, Maurice M, Jacquemin E. Liver diseases related to MDR3 (ABCB4) gene deficiency. Front Biosci 2009; 14: 4242-56.

  11. Gordo-Gilart R, Andueza S, Hierro L, Martínez-Fernández P, D’Agostino D, Jara P, Alvarez L. Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity. Gut 2015; 64: 147-55

  12. Alvarez L, Jara P, Sanchez-Sabaté E, Hierro L, Larrauri J, Díaz MC, Camarena C, et al. Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum Mol Genet 2004; 20: 2451-60.

  13. Martínez-Fernández P, Hierro L, Jara P, Alvarez L. Knockdown of ATP8B1 expression leads to specific down-regulation of the bile acid sensor FXR in HepG2 cells. Effect of the FXR agonist GW4064. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1119-G1129.

  14. Gautherot J, Delautier D, Maubert MA, Aït-Slimane T, Bolbach G, Delaunay JL, Durand-Schneider AM, et al. Phosphorylation of ABCB4 impacts its function: insights from disease-causing mutations. Hepatology 2014; 60: 610-21.

  15. Poupon R. Ursodeoxycholic acid and bile- acid mimetics as therapeutic agents for cholestatic liver diseases: An overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012; 36: 3-12.

  16. Friedman SL, Bansal MB. Reversal of hepatic fibrosis -fact or fantasy? Hepatology 2006; 43: 82-8.

  17. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.

  18. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-75.




2020     |     www.medigraphic.com